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SUMMARY. Stress urinary incontinence (SUI) is a common type of urinary incontinence in women, affecting large pro-
portion of women. Surgical methods, especially suburethral sling operations are the most important modes of the treat-
ment of SUI. Bulking agents were created as an alternative to conventional surgical methodsand may be the fi rst line of 
therapy in certain patients. Periurethral bulking implies implantation of various biocompatible agents around the urethra 
in order to improve coaptation of the urethral walls during intra-abdominal pressure elevation. The rates of cure are 
lower with bulking methods as compared with surgical techniques but are associated with a lower prevalence of postop-
erative complications. Bovine collagen remains the most frequently injected agent worldwide, with curerates of 53% at 
12 months after procedure. Polyacrylamide hydrogel and silicone micro implants have showed promising results, with 
about 64% improvement rate at 18 to 24 months after procedure. Application of urethral bulking agents is minimally 
invasive procedure and is mostly applied outpatientlyin local anesthesia. Urethral bulking agents are safe for clinical 
usage. Bulking agents should not berecommended as a method of fi nal cure because they only lead to short-term 
 improvement.
Introduction
Stress urinary incontinence (SUI) is the most com-
mon type of urinary incontinence in women, affecting a 
large proportion of middle-aged and elderly women. 
Surgical treatment generally includes placement of vag-
inal suburethral polypropylene suspension tapes (sling 
procedures). Sling methods are minimally invasive sur-
gical techniques that require short hospital stay. Sling 
methods are the gold standard in the management of 
SUI in women (1,2). Bulking procedureshave emerged 
as an alternative option to the standard surgical tech-
niques in the treatment of urinary incontinence in wom-
en and can be fi rst-line therapy in some patients (3). 
Bulking proceduresimply implantation of agents around 
the urethra. Bulking agents can be synthetic or biologic, 
and they compensate for the inadequate periurethral tis-
sue. The agent is applied into the urethral submucosa in 
order to improve coaptation of the urethral walls during 
intra-abdominal pressure elevation. There are several 
types of bulking agents, as follows: collagen, polydi-
methylsiloxane, silicone, carbon coated zirconium 
beads, polyacrylamide hydrogel, and hyaluronic acid/
dextranomer (4,5). In 1938, Murless described the use 
of sodium tetradecyl sulfate around the urethra in the 
treatment of urinary incontinence (6). Many bulking 
agents of various chemical compositions have been in-
troduced in clinical practice since 1990. Some agents 
have been withdrawn from the market due to side ef-
fects. An ideal periurethral agent for the treatment of 
SUI should be biocompatible, not inducing immune re-
action, should maintain bulking characteristics over 
long period, should not undergo degeneration and mi-
gration, must be safe and effi cient, and cause minimal 
tissue reaction. These agents can be applied in two 
ways, transurethral and periurethral. Bulking agent is 
applied by a needle, mostly under cystoscope guidance 
(7). Bulking agents should not be recommended as a 
method of defi nitive cure because they only lead to 
short-term improvement (8).
Urinary incontinence is involuntary loss of urine, 
thus posing a social and hygienic problem. Moderate to 
severe urinary incontinence involves 7% of women 
aged 20–39, 17% of women aged 40–59, 23% of wom-
en aged 60–79, and 32% of women aged >80 (9). It is 
classifi ed into three main types: stress incontinence, 
urge incontinence, and mixed incontinence. According 
to the International Continence Society (ICS), SUI is 
defi ned as urine leakage during physical activity, cough, 
and any activity associated with intra-abdominal pres-
sure elevation (10). Stress incontinence is caused by 
weakening of pelvic musculature and lesions of endo-
pelvic fascia. The risk factors for developing SUI in-
clude delivery, drugs for urethral sphincter relaxation, 
obesity, pulmonary diseases with chronic cough, and 
previous pelvic surgery (11). Urinary incontinence is 
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Figure 1. Cystoscopic view of proximal urethra and internal urethral ori-
fi ce before and after periurethral agent injection.
caused by the loss of anatomic support to the vesicoure-
thral junction, i.e. due to urethral hypermobility and in-
ternal urethral sphincter defi ciency. In terms of urody-
namics, SUI occurs when intravesical pressure exceeds 
maximal urethral closure pressure (12). According to 
McGuire classifi cation, SUI types I and II occur due to 
urethral hypermobility, whereas type III develops due to 
intrinsic urethral sphincter defi ciency (ISD) (13).
The Mechanism of Internal Sphincter 
Defi ciency and Action of Paraurethral 
Biomaterials
Two mechanisms have been proposed for the occur-
rence of stress incontinence, i.e. weakness of the ure-
thral supporting tissues resulting in urethral hypermo-
bility, and a defi cient mechanism of the urethral sphinc-
ter closure (ISD). It should be noted that these two 
mechanisms are not dichotomous but represent a con-
tinuum, thus many patients may show characteristics of 
both mechanisms (14). ISD is caused by damage to the 
system of sphincter innervation or to structures of the 
urethral sphincter mechanism, which consists of the 
striated muscle, smooth muscle, mucosa and submuco-
sa (14). The causes of the internal urethral sphincter de-
fi ciency include lesions associated with delivery, isch-
emic lesions, previous operations, and neurogenic 
causes. ISD is a condition where the urethral sphincter 
cannot achieve adequate tone to overcome the intraves-
ical pressure, in particular during the phase of bladder 
fi lling. In these patients, urine is frequently leaking con-
tinuously or at minimal exertion. Mechanical properties 
and structural integrity of the pelvic musculature, con-
nective tissue and ligaments are responsible for main-
taining continence in women (15,16). Damage and loss 
of mechanical properties of the endopelvic fascia is 
 believed to be a major factor in the development of SUI 
in women. Partial or complete denervation can lead to 
ISD (17).
Biomaterials injected periurethrally act by increasing 
coaptation of the urethral walls during the phase of 
bladder fi lling and in the period of elevated intra-ab-
dominal pressure (18). This mechanism restores conti-
nence by increasing urethral resistance. Bulking agents 
increase the volume of periurethral tissues (Fig 1), thus 
supporting the urethra and its angulation, which in turn 
facilitates closure of the urethra by increasing the ure-
thral closure pressure. Bulking agents have been tradi-
tionallyused in patients with ISD, with poorly compli-
ant bladder and normal anatomic support. Urethral 
bulking injections can be used in all types of stress in-
continence (19). Bulking agent injection should not 
 result in fi brosis. Injectable agents should be non-anti-
genic, acellular and sterile to minimize the rate of re-
jection and postoperative infl ammation. The micro-
polymer particles of non-biologic agents should exceed 
110 μmin size to prevent their dislocation and migra-
tion (20).
Indications for Use of Bulking Agents
The use bulking agents is indicated as follows: wom-
en with ISD; women with contraindication for the use 
of sling techniques due to comorbidity; women of gen-
erative age planning childbirth, thus refusing sling 
methods; women in whom the treatment of SUI by the 
sling method failed; and women preferring bulking 
method as the fi rst treatment modality (21). Each pa-
tient should be approached individually, respecting her 
preferences and expectations in the management of 
stress urinary incontinence. Urethral injections should 
not be used in case of urge incontinence and in patients 
with obstructive urinary disorders. In case of lower uri-
nary tract infection, insertion of periurethral implants 
should also be avoided due to the high risk of abscess 
formation.
The workup preceding the treatment with bulking 
agents consists of thorough history taking, urogyneco-
logical examination, measuring post-void residual urine 
and urine culture. In addition, voiding diary and urody-
namic testing are performed frequently to set the diag-
nosis of ISD. Voiding diary and measurement of urine 
output provide data on the bladder capacity, while uro-
fl owmetryindicates maximum urine fl ow rate. Cystom-
etry provides data on the bladder capacity and possible 
overactivity. Cystoscopy is another method that is help-
ful in diagnosing ISD by determination of bladder neck 
closure (22).
Types of Bulking Agents
Durasphere® consists of carbon coated zirconium 
beads dispersed in polysaccharide gel. At one year of 
application, the effi cacy of Durasphere® in the treat-
ment of ISD was superior to that of bovine collagen, 
with 80.3% versus 69.1% incontinence reduction. Du-
rasphere® was associated with a higher rate of urinary 
retention (23). Another study revealed that the durabil-
ity of this agent did not surpass that of bovine collagen; 
the more so, periurethral application of bovine collagen 
proved more successful in hysterectomized women 
(24). Durasphere® is injected via 18-gauge needle, usu-
ally transurethrally at the level of the bladder neck, 
guided by a cytoscope at 4.00 or 8.00 o’clock position; 
it can also be injected by the periurethral technique 
(25). The occurrence of periurethral masses has been 
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Figure 2. Urodex® injection system (with permission)
Figure 3. Urodex® Treatment kit (with permission)
recorded, with the incidence of 2.9% more than 12 
months of the application, as well as de novo symptoms 
of urinaryretention and bladder irritation (26).
Coaptite® is a synthetic biomaterial that consists of 
calcium hydroxylapatite microspheres suspended in 
carboxymethylcellulose gel. The effi cacy of Coaptite® 
is comparable to bovine collagen in terms of inconti-
nence symptom reduction. At 12 months of Coaptite® 
injection, signifi cant improvement of urinary conti-
nence was recorded in 64.3% of patients versus 57% for 
bovine collagen. The procedure of Coaptite® injection 
was only indicated for ISD treatment (27). There are 
several literature reports on the occurrence of granulo-
matous reaction with urethral prolapse following Coap-
tite® injection (28–30). Coaptite® is injected similar to 
Durasphere®, transurethrally under cytoscope guid-
ance.
Macroplastique® is made up of silicone polymers, 
polydimethylsiloxane, that are immersed in polyvinyl-
pyrrolidone gel (31). Its large particle diameter (>100 
μm) decreases the likelihood of particle migration. 
Polydimethylsiloxane elastomer and polyvinylpyrrol-
idone are characterized by very good biocompatible 
properties (32). In comparison with collagen agents, 
Macroplastique® is superior in improving urinary con-
tinence. At 12 months of implantation, the rate of conti-
nence improvement was 61.5% and 48% for Macro-
plastique® and Contigen®, respectively. The rate of 
cure for Macroplastique®in the same period was 36.9% 
(31). A systematic review of the relevant literature 
found the rate of cure and improvement for Macro-
plastique® to range from 14% to 66.7% and from 46% 
to 80%, respectively, whereas the rate of urinary reten-
tion was 5.9%–17.5% (32). Zullo et al. report on the 
18% rate of cure and 39% rate of improvement, where-
as the rate of failure at 60 months of the procedure was 
43% (33). Macroplastique® is generally implanted in 
local anesthesia, transurethrally under cystoscope guid-
ance. The agent is injected into the submucosa of proxi-
mal urethra at the 6.00, 10.00 and 2.00 o’clock posi-
tions. The procedure can also be performed by peri-
urethral technique. Besides conventional access under 
cystoscope guidance, a commercial system for implan-
tation of this agent that does not require cystourethros-
copy has been developed.
Periurethral collagen injection for the treatment of 
stress incontinence has been used since 1993 (34). Col-
lagen injection requires immune testing due to its anti-
genic properties. Collagen used as a bulking agent has 
been demonstrated to provide good results in the man-
agement of SUI caused by ISD (35). Collagen injected 
in the groups of patients with ISD and with hypermobile 
urethra resulted in comparable rates of improvement 
and cure in both groups. Urodynamic parameters indi-
cated improvement and cure in 46% of patients with 
ISD and 40.7% of patients with hypermobile urethra, 
demonstrating that hypermobile urethra is no a contra-
indication for use of bulking agents (36). Although col-
lagen is a safe agent, it cannot ensure long-term symp-
tom improvement and the majority of patients need 
 additional agent injections (36,37). Ultrasound studies 
revealed that most patients requiring additional colla-
gen applications had asymmetric collagen confi guration 
or small volume of the agent injected (38). Anti-incon-
tinence surgery prior to collagen application contributes 
to prolonged success of this biomaterial (39). Collagen 
can be injected transurethrally under cystoscope guid-
ance or by periurethral technique. It can be injected at 
multiple sites until the desired effect is achieved (40).
Bulkamid® is a synthetic hydrogel consisting of 2.5% 
polyacrylamide. This agent is biocompatible, durable, 
nontoxic, and has appropriate viscosity. At 24 months 
of Bulkamid® injection, 94% rate of patient satisfac-
tion, 54% rate of improvement and 14% rate of cure 
were recorded (41). A favorable effect of Bulkamid® 
has been reported in women having previously under-
gone anti-incontinence surgery (42). A comprehensive 
literature review revealed that 24.3% of women re-
quired repeat Bulkamid® implantation to maintain its 
effi cacy. The most common side effects were pain and 
urinary tract infections (43). In comparison with colla-
gen, Bulkamid® maintained high rates of symptom im-
provement and cure (44). This agent has a favorable and 
longer effect on the symptoms of SUIwith a low risk of 
serious side effects.
NASHA/Dx (non-animal stabilized hyaluronic acid/
dextranomer) is a copolymer containing dextranomer 
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microspheres in non-animal hyaluronic acid gel. The 
agent is biocompatible, biodegradable, free from immu-
nogenic properties, and demonstrated not to migrate to 
other organs. Dextranomer consists of hydrophilic dex-
tran polymer particles (80–120 μm). Hyaluronic acid is 
1% solution of high viscosity and high molecular weight 
polysaccharides (40). A number of studies have shown 
it to be effi cacious and well tolerated in the treatment of 
SUI (45–47). The following complications associated 
with the use of NASHA/Dx have been reported to date: 
periurethral masses, urethral granulomata, urethral ab-
scesses, and pseudocysts (48–51). A special commer-
cial NASHA/DxImplacer™ device has been designed, 
thus no cystoscope guidance being required on its im-
plantation (52). Magnetic resonance imaging (MRI) 
studies have demonstrated that the agent is injected at 
appropriate sites of the urethral wall without the need of 
endoscopic guidance (53). The Implacer™ is a plastic 
guide with 4 holes through which the syringe needles 
are passed. Similar NASHA/Dxapplication device 
(Urodex®) is available on Croatian market (Fig. 2,3). 
The procedure is usually performed outpatiently in lo-
cal anesthesia.
Ethylene vinyl alcoholwas approved for use as a 
bulking agent in 2004, and its effi cacy was demonstrat-
ed in 45% of patients at 51 months of injection (54). 
However, the associated side effects such as urethral 
erosions were a matter of concern, thus this agent was 
withdrawn from the market (55).
Comparison of the effi cacy of porcine dermal implant 
and Macroplastique® yielded higher cure rates with the 
former at 6 months of implantation (56). Autologous 
myoblast implants have been studied as an agent for 
periurethral application in the treatment of stress uri-
nary incontinence. Myoblasts can differentiate periure-
thrally into muscle fi ber. Studies failed to demonstrate 
the effi cacy of this material in increasing the volume of 
urethral walls as the substantial determinant of bulking 
agents (57).
Techniques of Bulking Agents Implantation
Transurethral approach enables direct visualization 
of the urinary canal and facilitates accurate agent ap-
plication (58). This technique requires use of a lower 
agent volume (59). In transurethral technique, the cys-
toscope is inserted centrally in the urethra and the nee-
dle penetrates the urethral mucosa at about 1.5 cm dis-
tally from the bladder neck (60). Periurethral approach 
has been ever more widely adopted for avoiding trauma 
to the urethra and leak of the agent (59). The needle is 
inserted laterally along the external orifi ce of urethra on 
vaginal introitus under cystoscope guidance; then the 
needle is moved along the urethra to the bladder neck. 
There were no major differences in the effi ciency of 
these two techniques but patients having undergone 
transurethral approach had less urinary retention (59).
The implantation devices that do not require cysto-
scope guidance have been designed for a number of 
agents, e.g., Macroplastique®, Zuidex® and Urolas-
tic® (45,61,62). These devices are based on previous 
urethra measurement by a catheter and device adjust-
ment for the needle to reach a length slightly shorter 
than the urethra, i.e. to reach the bladder neck and prox-
imal urethra. The devices are intended for both trans-
urethral and periurethral approaches. Effi ciency rates 




Patients are instructed to discontinue anticoagulant 
drugs for 7 days before the application of bulking mate-
rials. A broad-spectrum antibiotic as prophylaxis is ad-
ministered for 3 days of biomaterial injection. In case of 
post-procedural urinary retention, urinary bladder self-
catheterization is performed. Periurethralbiomaterial 
injection is performed in local anesthesia with 1% lido-
caine solution (58). Upon agent injection, the patient’s 
urinary continence at exertion is reassessed. Adequate 
patient hydration and avoiding sexual activity for at 
least one week is recommended. Follow up of the 
mechanism ofmicturition is scheduled in one month 
(60). The most common complications of these agents 
are urinary tract infections. Temporary urinary reten-
tion, urgency incontinence and transient hematuria may 
also occur (23,27). Pain and discomfort may persist for 
24 hours postoperatively (58). The biomaterials intend-
ed for periurethral implantation should be safe for use, 
not associated with any major side effects such as gran-
uloma, abscess or urethral mucosa erosion, and not 
prone to migration. The use of autologous fat has been 
discontinued due to particle migration and report on pa-
tient death from pulmonary embolism (64). Tefl on has 
not been approved for use as a bulking agent by the US 
Food and Drug Administration due to proven particle 
migration to lymph nodes and distant organs, and carci-
nogenic effects (65,66). Zuidex® has been withdrawn 
from market in the USA because it caused development 
of sterile abscesses and infections (67). Urethral pro-
lapse is a complication associated with several bulking 
agents (68,69).
Effi cacy of Bulking Agents
Generally, bulking agents lead to improvement in pa-
tient condition. Improvement in the quality of life after 
implantation of these agents is comparable to surgical 
methods (70). Surgical methods used in the manage-
ment of SUIwere found to have longer effects and high-
er rates of cure at 12 months (71). Injection of silicone 
agents, calcium hydroxyapatite, carbon particles and 
hyaluronic acid dextranomer resulted in improvements 
comparable to collagen injection (71). Studies have 
shown the Macroplastique® agent to be characterized 
by longest durability at 2 years. Signifi cant improve-
ment on Stamey grading scale was recorded in 84% of 
patients at 12 months of the procedure, whereas two-
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Table 1. Outcomes of treatment with conventional surgical techniques and bulking methods. According to: Leone Roberti Maggiore et al. (7).With 
permission of author.
Author Objective success defi nition
Objective recurrence (n, %)
Subjective success defi nition
Subjective recurrence (n, %)
Surgery Bulking Surgery Bulking
Maher et al. (75) No urinary leakage 






Women with no or occasional 





Corcos et al. (76) Having dry 24-h pad test 






Answers “Somewhat satisfi ed” 
or ‘Satisfi ed” at the question 






Gaddi et al. (77) Negative stress test 
no urodynamic stress 
incontinence and 





No symptoms of SUI 
(involuntary leakage on effort 
or exertion or on sneezing 
or coughing)
 –  –
SUI = stress urinary incontinence
thirds were free from incontinence discomforts at 24 
months (72). A meta-analysis of the effi cacy of Macro-
plastique® showed a 73% rate of incontinence im-
provement in 6–18 months and 64% rate of symptom 
improvement at 18 months of the procedure (21). The 
effi cacy of Durasphere® is variable. A large random-
ized study reports on 80.3% improvement at 12 months 
(23). Improvement of grade 1 incontinence according to 
Stamey was recorded in 80% of patients, while 40% of 
patients were completely free from urinary inconti-
nence (73). A similar study found 33% effi cacy of Du-
rasphere® at 2 years (24). Coaptite® resulted in 63.4% 
improvement of urinary incontinence at 12 months of 
implantation, while cure was recorded in 39% of pa-
tients (27).
Bulking Methods and Surgical Techniques 
in the Treatment of Stress Urinary 
Incontinence
Kirchin et al. report on signifi cantly better rates of 
objective improvement after treatment with conven-
tional surgical methods than with the application of 
bulking agents (71). The rate of cure is lower with the 
latter, but the use of bulking agents is associated with 
less postoperative complications (74). A comprehensive 
meta-analysis compared surgical methods and bulking 
agents in the management of urinary incontinence and 
found the difference in effi cacy between the two ap-
proaches to be lesser than previously believed, yet 
pointing to the advantages of surgical methods (7). The 
outcomes of SUItreatment by bulking agents and con-
ventional surgical techniques are illustrated in Table 1.
Maher et al. investigated the effi cacy of Macroplas-
tique® and sling methods in the treatment of ISD. The 
objective effi cacy of sling methods was signifi cantly 
higher as compared with this bulking material (81% vs. 
9%) at 12–15 months of the procedure. Morbidity was 
signifi cantly lower with Macroplastique®. At 62 
months, the rates of urinary continence and patient sat-
isfaction were considerably higher in the sling group 
(69% vs. 21% and 69% vs. 29%, respectively) (75).
Corcos et al. compared the effi cacy of paraurethral 
collagen (n=66) and surgical methods (n=67) in the 
management of stress urinary incontinence. At 12 
months of the procedure, the rate of successful outcome 
was 53.1% in the collagen group and 72.2% in the sur-
gical treatment group. The rate of patient satisfaction 
was higher in the group having undergone conventional 
surgical methods than in those treated by paraurethral 
collagen injections (79.6% vs. 67.2%), with statistically 
nonsignifi cant between-group difference (p=0.228). 
The rate of complications was lower in the collagen 
group (76).
After failure of treatment with sling methods, Gaddi 
et al. compared the effi cacy of repeated sling methods 
with bulking procedures in a retrospective cohort study. 
In a total of 165 patients, 11 (11.2%) failures were re-
corded in the group with sling methods and 26 (38%) 
failures in the group with bulking technique. There was 
no between-group difference in the rate of perioperative 
complications. Multivariate logistic regression showed 
the risk of failure to be signifi cantly higher in the bulk-
ing group as compared with the sling group (OR 3.49; 
CI 1.34-9.09; p=0.01) (77).
Conclusion
Bulking agents provide a minimally invasive ap-
proach in the treatment of SUI, which greatly reduces 
quality of life in affected women. In properly selected 
patients, the urethral bulking injection is an appropriate 
alternative to surgical methods of SUI treatment. These 
periurethralagents have shown acceptable rates of cure 
and improvement in the management of SUI. ISD is the 
main indication for the use of bulking agents. On choos-
ing the method of treatment of SUI, patient goals and 
outcome expectations should be taken in consideration. 
According to meta-analyses and large studies, periure-
thral biomaterials should not be recommended as fi rst-
line therapy in women seeking permanent cure because 
the improvement thus achieved is short-lived with most 
bulking agents (7). The cure rates are lower with bulk-
ing procedures as compared with surgical techniques, 
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however, the former are associated with a considerably 
lower prevalence of postoperative complications. Bo-
vine collagen (Contigen®) remains the most frequently 
injected agent worldwide, with up to 53% cure rates at 
12 months, but its disadvantage is shorter durability. 
Polyacrylamide hydrogel (Bulkamid®) showed prom-
ising medium-term results, with 64% improvement rate 
at 24 months. All the biomaterials described have better 
durability than collagen, but have some other draw-
backs. Duraphere® has a more demanding mode of ap-
plication, whereas Coaptite® and Zuidex® more fre-
quently cause development of urethral granulomas and 
abscesses (78). Macroplastique® has been shown to be 
an effi cacious and durable material with a low rate of 
complications (32). Based on the literature review, it is 
concluded that the majority of urethral bulking agents 
are safe for implantation. Their advantage is that they 
can be injected in local anesthesia, which is in particular 
favorable in patients with various comorbidities (7). 
Bulking agents should be offered as an alternative to 
patients that do not want to undergo conventional surgi-
cal treatment of SUI(7). Currently, there is no consen-
sus about the best biomaterial and the best technique of 
their application.
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PRIMJENA PERIURETRALNIH BIOSREDSTVA U LIJEČENJU 
STATIČKE INKONTINENCIJE MOKRAĆE U ŽENA
Krešimir Živković1, Damir Hodžić2, Nikica Živković3, Dragan Soldo4, 
Mario Kordić4, Berivoj Mišković1, Slavko Orešković5
Pregledni članak
Ključne riječi: statička inkontinencija mokraće, žene, uretralna bulking sredstva, suburetralni slingovi
SAŽETAK. Statička inkontinencija mokraće česta je vrsta inkontinencije mokraće u žena. Kirurške metode, a pogotovo 
suburetralne sling operacije najvažniji su modaliteti liječenja statičke inkontinencije mokraće. Periuretralna bulking 
sredstva stvorena su kao alternativa konvencionalnim kirurškim metodama i mogu biti prvi izbor terapije kod nekih 
pacijentica. Periuretralni bulking označava implantaciju različitih biokompatibilnih sredstava oko uretre kako bi se 
poboljšala koaptacija stijenki uretre tijekom povećanja intraabdominalnog tlaka. Stope izlječenja bulking sredstvima su 
niže u usporedbi s kirurškim tehnikama, ali zato imaju nižu pojavnost poslijeperacijskih komplikacija. Goveđi kolagen 
najčešće je aplicirani periuretralni biometerijal u svijetu, stope izlječenja su do 53% u roku od 12 mjeseci nakon zahva-
ta. Poliakrilamidhidrogel i silikonski mikroimplantati pokazali su obećavajuće rezultate od 18 do 24 mjeseca nakon 
postupka sa stopom poboljšanja od oko 64%. Postavljanje periuretalnih sredstava spada u minimalno invazivne metode 
i uglavnom se primjenjuje ambulantno u lokalnoj anesteziji. Periurethralni biomaterijali sigurni su za kliničku upotrebu. 
Bulking sredstva ne bi trebala biti razmatrana kao trajno rješenje s obzirom na to da dovode samo do kratkotrajnog 
poboljšanja.
